Breaking News Instant updates and real-time market news.

AZN

AstraZeneca

$37.87

(0.00%)

, GSK

GlaxoSmithKline

$39.56

0.2 (0.51%)

11:46
10/25/18
10/25
11:46
10/25/18
11:46

Wells Fargo says Trump speech today won't be end of drug pricing proposals

Wells Fargo analyst David Maris notes that Politico and other media outlets are reporting that President Donald Trump will propose several new initiatives to address high drug prices when he speaks later today at the U.S. Department of Health and Human Services. Maris thinks Trump's focus will be on how other countries are "freeloading" on U.S. innovation with lower negotiated pricing, stating that news reports make it appear that the administration is targeting the industry for action, rather than other countries to raise their spending. While Maris acknowledges the timing of the speech being near the mid-term elections, he believes these proposals are simply the follow-though of earlier promises. He also expects this is not the end of proposals to address the issue of U.S. drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

AZN

AstraZeneca

$37.87

(0.00%)

GSK

GlaxoSmithKline

$39.56

0.2 (0.51%)

BMY

Bristol-Myers

$49.00

0.14 (0.29%)

PFE

Pfizer

$43.81

1.33 (3.13%)

NVS

Novartis

$85.28

1.025 (1.22%)

RHHBY

Roche

$0.00

(0.00%)

LLY

Eli Lilly

$108.26

1.89 (1.78%)

MRK

Merck

$69.91

-0.64 (-0.91%)

JNJ

Johnson & Johnson

$138.71

1.2 (0.87%)

SNY

Sanofi

$42.93

0.59 (1.39%)

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

  • 06

    Nov

  • 07

    Nov

  • 12

    Nov

  • 24

    Dec

  • 11

    Jan

  • 28

    Jan

  • 16

    Feb

  • 22

    Mar

  • 28

    Apr

  • 20

    May

AZN AstraZeneca
$37.87

(0.00%)

10/22/18
CANT
10/22/18
NO CHANGE
Target $68
CANT
Overweight
Tesaro price target raised to $68 from $57 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young raised her price target for Tesaro (TSRO) to $68 saying AstraZeneca's (AZN) presented the Solo1 study using olaparib as a first-line treatment for BRCA ovarian cancer patients is positive for Tesaro's first-line study Prima study, with data expected in the second half of 2019. AstraZeneca's data clearly support broad use in first-line "at least" for BRCA ovarian cancer patients, which is positive for the PARP inhibitor class, Young tells investors in a research note. The analyst increased PARP inhibitor penetration in the BRCA patient at peak to 75% from 65% and reiterates an Overweight rating on Tesaro.
10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/23/18
WOLF
10/23/18
INITIATION
WOLF
Outperform
AstraZeneca reinitiated with an Outperform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated AstraZeneca with an Outperform.
10/24/18
CANT
10/24/18
NO CHANGE
Target $68
CANT
Overweight
Cantor Fitzgerald sees nothing fundamental for Tesaro weakness
Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating and $68 price target on Tesaro's (TSRO) shares as she sees nothing fundamental on recent weakness. While she acknowledges that the stock is down around 28% since ESMO, the analyst pointed out that the AstraZeneca's (AZN) SOLO1 data is a positive read for the niraparib PRIMA study that will read out in 2H 2019. Further, Young believes that key catalysts for Tesaro remain SITC - GARNET and AMBER data, pivotal data in endometrial for its PD-1 licensed from AnaptysBio (ANAB), and PRIMA data in first line ovarian in 2H 2019.
GSK GlaxoSmithKline
$39.56

0.2 (0.51%)

10/23/18
WOLF
10/23/18
INITIATION
WOLF
Peer Perform
GlaxoSmithKline reinitiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated GlaxoSmithKline with a Peer Perform.
10/08/18
GUGG
10/08/18
INITIATION
GUGG
Neutral
GlaxoSmithKline initiated with a Neutral at Guggenheim
Guggenheim analyst Seamus Fernandez started GlaxoSmithKline with a Neutral rating and 1,679p price target, stating that he views its upside more in the consumer side than in pharma. The company's oncology and immunology pipeline could emerge, but it is still a bit early to tell, Fernandez added in his initiation note.
09/19/18
MSCO
09/19/18
NO CHANGE
MSCO
Equal Weight
Morgan Stanley says AbbVie market cap fell more than largest drug settlement
After AbbVie (ABBV) slid about 3% yesterday following a California Insurance Commissioner lawsuit alleging Humira kickbacks, Morgan Stanley analyst David Risinger noted its $4B loss in market cap was larger than GlaxoSmithKline's (GSK) previous $3B settlement for violations under the False Claims Act, which he called the biggest ever historical pharma settlement. While Commissioner Dave Jones claims imply that the potential fine for Abbvie could theoretically be more than $3B, Risinger also noted that the company told him it believes the allegations "are completely without merit." He maintains an Equal Weight rating and $100 price target on AbbVie shares.
BMY Bristol-Myers
$49.00

0.14 (0.29%)

10/23/18
WOLF
10/23/18
INITIATION
Target $66
WOLF
Outperform
Bristol-Myers reinitiated with an Outperform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Bristol-Myers with an Outperform and $66 price target.
10/22/18
SBSH
10/22/18
DOWNGRADE
Target $57
SBSH
Neutral
Citi sees Merck showing 'extraordinary' treatment effect, downgrades Bristol
Citi analyst Andrew Baum downgraded Bristol-Myers Squibb (BMY) to Neutral from Buy and lowered his price target for the shares to $57 from $62. The drugmaker closed Friday down 3%, or $1.72, to $54.30. The downgrade largely reflects further likely "lowering of floor" Opdivo, Yervoy and earnings estimates from a base that is already materially below the consensus, Baum tells investors in a research note partially titled "The Final Straws." The analyst anticipates an "extraordinary" treatment effect from Keytruda in Merck's (MRK) Keynote-426 trial in renal cell carcinoma given the statistical significance for both progression-free survival and overall survival at the first interim analysis.
10/22/18
HCWC
10/22/18
NO CHANGE
Target $54
HCWC
Neutral
Roche data should concern Nektar bulls, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay believes Roche's (RHHBY) preliminary data of RO6875281, a fibroblast activation protein targeted interleukin-2 variant, should concern the bulls of Nektar Therapeutics (NKTR). The 11% and 20% overall response rate for single agent RO6875281 in squamous cell head and neck cancer and melanoma is compelling, Chattopadhyay tells investors in a research note. Nektar's NKTR-214 had no monotherapy activity, and the early promise in combination with Opdivo "has faded potentially due to its limited PK profile," the analyst adds. In addition, Chattopadhyay believes the monotherapy activity with pegilodecakin, a pegylated IL-10 being developed by Eli Lily (LLY), further complicates the competitive landscape for NKTR-214. He believes the second generation of "not alpha" IL-2, which is poised to enter the clinic during 2019, could further "upend" NKTR-214 and might compel Nektar's partner Bristol-Myers Squibb (BMY) to "re-evaluate the aggressive development strategy that was outlined earlier this year." The analyst keeps a Neutral rating on Nektar with a $54 price target.
10/22/18
10/22/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. eBay (EBAY) downgraded to Neutral from Buy at Monness Crespi and BofA/Merrill. 2. Bristol-Myers (BMY) downgraded to Neutral from Buy at Citi. 3. Manpower (MAN) downgraded to Neutral from Overweight at JPMorgan with analyst Andrew Steinerman saying he "misjudged the magnitude" of the European softness for the company as its Q4 financial guidance suggests a down 2% year-over-year same day basis revenue decline. 4. Reliance Steel (RS) downgraded to Neutral from Buy at Longbow with analyst Chris Olin citing near-term risks from unfavorable nonferrous demand/price momentum following a collection of relatively weak data points from the firm's carbon and stainless steel surveys. 5. Wingstop (WING) downgraded to Neutral from Outperform at Wedbush with analyst Nick Setyan saying he continues to believe drivers of same-store sales growth, unit growth, and margin upside relative to current consensus 2018 and 2019 estimates exist. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
PFE Pfizer
$43.81

1.33 (3.13%)

10/23/18
WOLF
10/23/18
INITIATION
Target $46
WOLF
Peer Perform
Pfizer reinitiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Pfizer with a Peer Perform and $46 price target.
10/02/18
PIPR
10/02/18
NO CHANGE
Target $100
PIPR
Neutral
AbbVie scripts for Humira relatively weak in Q3, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond says new survey data from dermatologists and gastroenterologists indicate AbbVie's (ABBV) Humira is losing share faster in psoriasis and inflammatory bowel disease than in rheumatoid arthritis. In that management has called out psoriasis as a key driver of growth, the survey feedback may help explain Humira's relatively weak script trends for Q3, Raymond tells investors in a research note. The analyst believes dermatologists are embracing newer biologics such as Johnson & Johnson's (JNJ) Tremfya while gastroenterologists favor Takeda's Entyvio and increasingly Pfizer's (PFE) Xeljanz. Raymond remains cautious on shares of AbbVie ahead of European biosimilar erosion he expects to start this month. He keeps a Neutral rating on the stock with a $100 price target.
10/08/18
GSCO
10/08/18
NO CHANGE
Target $36
GSCO
Sell
Ionis' Tegsedi to face commercial headwinds, says Goldman Sachs
After the FDA approved Ionis (IONS) and affiliate Akcea Therapeutics' (AKCA) Tegsedi for adult polyneuropathy of hereditary transthyretin-mediated amyloidosis, but with a black box warning, Goldman Sachs analyst Salveen Richter said he believes the drug faces commercial headwinds. He cites the underlying safety profile and requirement for consistent monitoring as well as the recent launch of Alnylam's (ALNY) Onpattro and expected launch of Pfizer's (PFE) tafamidis in the first half of 2019. Richter keeps a Sell rating on Ionis shares with a price target of $36.
NVS Novartis
$85.28

1.025 (1.22%)

10/18/18
WEDB
10/18/18
DOWNGRADE
WEDB
Neutral
Endocyte downgraded to Neutral from Outperform at Wedbush
Wedbush analyst David Nierengarten downgraded Endocyte (ECYT) to Neutral after the company agreed to be acquired by Novartis (NVS) for $24 per share. The analyst does not next another bidder to emerge.
10/19/18
WELS
10/19/18
DOWNGRADE
WELS
Market Perform
Endocyte downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough downgraded Endocyte (ECYT) to Market Perform from Outperform, citing the company's deal to be acquired by Novartis (NVS). He believes that the proposed acquisition price of $24 per share fairly reflects the potential value of the company's lead PSMA-targeted radionuclide therapeutic and sees Novartis as best positioned to realize that value based on its leadership in radionuclide therapeutics. Birchenough sees low odds of a competing offer and low risk of a material event to derail the acquisition, he added.
10/23/18
WOLF
10/23/18
INITIATION
WOLF
Outperform
Novartis reinitiated with an Outperform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Novartis with an Outperform.
10/19/18
HCWC
10/19/18
NO CHANGE
Target $36
HCWC
Buy
Xoma 'undeservedly and overly punished' after CRL, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered his price target for Xoma (XOMA) to $36 from $49 after the company's partner Novartis (NVS) disclosed the receipt of a Complete Response Letter from the FDA in response to its application for the claim of cardiovascular risk reduction filed for canakinumab. Though canakinumab is one of the lead contributors to Xoma's valuation, the company's shares have been "undeservedly and overly punished," Pantginis tells investors in a research note. He remains focused on Xoma continuing to diversify its risk profile, highlighted by its recent Agenus (AGEN) transaction. He believes the company's numerous "shots on goal" present a "compelling opportunity" at current share levels.
RHHBY Roche
$0.00

(0.00%)

10/24/18
PIPR
10/24/18
NO CHANGE
Target $177
PIPR
Overweight
Piper 'perplexed' by Alexion earnings selloff, says buy shares
Piper Jaffray analyst Christopher Raymond recommends using the selloff today in shares of Alexion Pharmaceuticals (ALXN) as a buying opportunity. The company reported "yet another strong beat/raise quarter and continued impressive pipeline progress," Raymond tells investors in a research note. The analyst sees "little to quibble with commercially" with Soliris' "continued strength and a rapidly expanding margin profile." Raymond is "perplexed" by the stock pullback and keeps an Overweight rating on Alexion with a $177 price target. The stock could be weak on fears over Roche's (RHHBY) update on RG6107, the analyst adds. He says Alexion remains one of his favorite large caps to own "well into 2019."
10/22/18
PIPR
10/22/18
NO CHANGE
Target $200
PIPR
Overweight
Loxo 'highly likely' to win FDA approval next month, says Piper Jaffray
Loxo Oncology (LOXO) this weekend reported updated durability data for the original 55 TRK fusion patients treated with larotrectinib plus initial efficacy data from 54 newly-evaluable patients, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. He points out that the new patient dataset displayed a nearly identical response rate and that duration is tracking similarly with three quarters of patients maintaining a response out to a year. The updated larotrectinib data compare well to Roche's (RHHBY) competing entrectinib and makes the drug "highly likely" to be approved on or by the November 26 FDA action date, contends Van Buren. He reiterates an Overweight rating on Loxo Oncology with a $200 price target.
10/23/18
WOLF
10/23/18
INITIATION
WOLF
Peer Perform
Roche reinitiated with a Peer Perform at Wolfe Research
LLY Eli Lilly
$108.26

1.89 (1.78%)

10/23/18
WOLF
10/23/18
INITIATION
Target $119
WOLF
Peer Perform
Eli Lilly reinitiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Eli Lilly with a Peer Perform and $119 price target.
10/15/18
FBCO
10/15/18
INITIATION
Target $36
FBCO
Neutral
Elanco initiated with a Neutral at Credit Suisse
Credit Suisse analyst Erin Wright started Elanco (ELAN) with a Neutral rating and $36 price target. As the fourth-largest animal health therapeutics company, Elanco is highly levered to robust industry fundamentals across livestock and companion animal markets, and earnings growth should accelerate on dedicated innovation efforts and dramatically improving cost structure as a more nimble unencumbered entity, unchained to Eli Lilly (LLY), its large pharmaceutical parent, she contends.
MRK Merck
$69.91

-0.64 (-0.91%)

10/22/18
BMOC
10/22/18
NO CHANGE
Target $82
BMOC
Outperform
Merck price target raised to $82 from $70 at BMO Capital
BMO Capital analyst Alex Arfaei raised his price target on Merck to $82 and kept his Outperform rating, also raising his FY18 EPS view by 18c to $4.01 and FY19 view by 27c to $4.29. The analyst cites his increased confidence around the long-term growth potential of Keytruda and Gardasil and anticipates the company's revenue growing by mid-single digits until the loss of exclusivity for its Januvia program in 2022-23. Arfaei adds that his long-term forecasts are more bullish relative to the Street, with an added catalyst coming from Merck's potential diversification into Animal Health.
10/22/18
WBLR
10/22/18
NO CHANGE
WBLR
Merck data will dampen enthusiasm for Aduro Biotech, says William Blair
Merck (MRK) over the weekend presented the first-in-human data with a STING agonist, MK-1454, as monotherapy and in combination with Keytruda, William Blair analyst Matt Phipps tells investors in a research note. Overall, the lack of monotherapy responses and 24% overall response rate in combination with Keytruda across a variety of tumor types is "underwhelming" given the promising preclinical results seen with multiple STING agonists and industry enthusiasm for the target, the analyst contends. He believes investor enthusiasm for the upcoming poster with Aduro Biotech's (ADRO) STING agonist, ADU-S100, at the Society for the Immunotherapy of Cancer meeting "will undoubtedly be dampened." However, Phipps thinks it is premature to make final judgments on targeting STING in cancer immunotherapy based on Merck's small sample size of injections into one lesion. He has an Outperform rating on Aduro Biotech.
10/23/18
WOLF
10/23/18
INITIATION
Target $90
WOLF
Outperform
Merck reinitiated with an Outperform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated Merck with an Outperform and $66 price target.
JNJ Johnson & Johnson
$138.71

1.2 (0.87%)

10/23/18
PIPR
10/23/18
NO CHANGE
PIPR
Overweight
Piper says Theravance data shows 'disruptive potential' of oral JAK inhibitor
After Theravance Biopharma (TBPH) presented four-week data from the Phase Ib ulcerative colitis study of TD-1473, a gut-selective pan-JAK inhibitor for the treatment of inflammatory bowel disease, at the United European Gastroenterology Week, Piper Jaffray analyst Tyler Van Buren said the data provides substantial proof of concept and shows the "disruptive potential" that could lead to "multi-billion" global sales for Theravance and partner Janssen (JNJ). He maintains an Overweight rating on Theravance shares.
10/17/18
WELS
10/17/18
NO CHANGE
Target $160
WELS
Outperform
Johnson & Johnson price target raised to $160 from $155 at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen raised his price target for Johnson & Johnson to $160 from $155 following quarterly results. The analyst reiterates an Outperform rating on the shares.
10/24/18
JEFF
10/24/18
NO CHANGE
Target $50
JEFF
Buy
Pacira's strong Exparel trends continue, says Jefferies
Jefferies analyst David Steinberg says the 30.3% year-over-year gain for Symphony Health sales data in September suggests Pacira Pharmaceuticals' (PCRX) Exparel is continuing to accelerate. Exparel has now posted double digit year-over-year gains in 11 of the last 12 months arguably due to a strong nerve block launch and a Johnson & Johnson (JNJ) partnership that "may be hitting stride," Steinberg tells investors in a research note. The analyst sees the possibility for "significant upside" next year due to Centers for Medicare & Medicaid Services' unbundling in the ambulatory care setting. He keeps a Buy rating on Pacira with a $50 price target.
SNY Sanofi
$42.93

0.59 (1.39%)

10/23/18
WOLF
10/23/18
INITIATION
WOLF
Peer Perform
Sanofi reinitiated with a Peer Perform at Wolfe Research
10/17/18
JEFF
10/17/18
NO CHANGE
Target $31
JEFF
Buy
Jefferies still sees 'major' opportunity for Optinose after Dupixent data
Optinose (OPTN) shares underperformed yesterday following the positive Phase 3 results for Sanofi (SNY) and Regeneron's (REGN) Dupixent in treating patients with chronic rhinosinusitis with nasal polyps, Jefferies analyst David Steinberg tells investors in a research note titled "Biologics Competitor as Expected; Real World Pricing Issues Likely to Limit Us." The analyst says that while Dupixent demonstrated strong efficacy, clinicians he's spoken with believe that the "massive" pricing disparity versus nasal steroids will likely result in payer "step edits" that could limit widespread adoption of the "expensive" biologics currently under development. Further, Dupixent's head-to-head comparison with Optinose's Xhance's "strong" efficacy profile is difficult, the analyst adds. Steinberg still sees a "major" long-term opportunity for Xhance and keeps a Buy rating on Optinose with a $31 price target.
10/11/18
PIPR
10/11/18
NO CHANGE
Target $450
PIPR
Overweight
Piper remains buyer of Regeneron ahead of October 20 FDA action date
Piper Jaffray analyst Christopher Raymond says he remains a buyer of Regeneron Pharmaceuticals (REGN) ahead of the Dupixent asthma October 20 FDA action date. With consensus expecting this indication to contribute well over $1B in revenue in coming years, approval is a "critical near-term catalyst" for the shares, Raymond tells investors in a research note. The analyst adds that while some investors have expressed angst over the breadth of the label, namely restricting use to eosinophilic asthma, he believes recent Sanofi (SNY) commentary provides reason for optimism. The totality of clinical data and the biology behind Dupixent supports a broad label, Raymond contends. He maintains an Overweight rating on Regeneron with a $450 price target.

TODAY'S FREE FLY STORIES

INCY

Incyte

$81.22

0.72 (0.89%)

13:39
05/24/19
05/24
13:39
05/24/19
13:39
Hot Stocks
FDA approves expanded indication for Incyte's Jakafi »

According to a post to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    May

  • 31

    May

  • 05

    Jun

  • 10

    Jun

  • 11

    Jun

  • 13

    Jun

  • 17

    Jun

MOMO

Momo

$25.94

-0.72 (-2.70%)

13:35
05/24/19
05/24
13:35
05/24/19
13:35
Options
Momo put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

  • 11

    Jun

ALPN

Alpine Immune Sciences

$5.27

-0.34 (-6.06%)

, ADAP

Adaptimmune

$3.62

-0.03 (-0.82%)

13:34
05/24/19
05/24
13:34
05/24/19
13:34
Recommendations
Alpine Immune Sciences, Adaptimmune, Gilead analyst commentary  »

Alpine Immune Sciences…

ALPN

Alpine Immune Sciences

$5.27

-0.34 (-6.06%)

ADAP

Adaptimmune

$3.62

-0.03 (-0.82%)

GILD

Gilead

$66.88

-0.27 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 13

    Jun

  • 17

    Jun

ALPN

Alpine Immune Sciences

$5.27

-0.34 (-6.06%)

, GILD

Gilead

$66.91

-0.24 (-0.36%)

13:30
05/24/19
05/24
13:30
05/24/19
13:30
Hot Stocks
Alpine Immune Sciences reports notice of termination of license pact with Kite »

In a regulatory filing…

ALPN

Alpine Immune Sciences

$5.27

-0.34 (-6.06%)

GILD

Gilead

$66.91

-0.24 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 13

    Jun

NVS

Novartis

$88.00

3.54 (4.19%)

, BIIB

Biogen

$228.00

-1.05 (-0.46%)

13:30
05/24/19
05/24
13:30
05/24/19
13:30
Hot Stocks
ICER says Zolgensma price falls within upper bound of benchmark range »

The Institute for…

NVS

Novartis

$88.00

3.54 (4.19%)

BIIB

Biogen

$228.00

-1.05 (-0.46%)

IONS

Ionis Pharmaceuticals

$65.44

-1.69 (-2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 31

    May

  • 05

    Jun

  • 06

    Jun

  • 17

    Jun

  • 18

    Jun

GOLD

Barrick Gold

$11.93

-0.03 (-0.25%)

, ABGLF

Acacia Mining

$0.00

(0.00%)

13:23
05/24/19
05/24
13:23
05/24/19
13:23
Periodicals
Barrick CEO tells Reuters Acacia bid reflects Tanzania risk »

Barrick Gold (GOLD) CEO…

GOLD

Barrick Gold

$11.93

-0.03 (-0.25%)

ABGLF

Acacia Mining

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
05/24/19
05/24
13:17
05/24/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
05/24/19
05/24
13:16
05/24/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTSH

Cognizant

$61.83

0.75 (1.23%)

13:12
05/24/19
05/24
13:12
05/24/19
13:12
Hot Stocks
Cognizant CEO buys 19K shares of company stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

  • 23

    Jun

NFLX

Netflix

$355.84

3.61 (1.02%)

, GOOG

Alphabet

$1,144.00

3.45 (0.30%)

13:08
05/24/19
05/24
13:08
05/24/19
13:08
Hot Stocks
Netflix to release 'Little Black Mirror' episodes on YouTube starting May 26 »

Netflix Latin America…

NFLX

Netflix

$355.84

3.61 (1.02%)

GOOG

Alphabet

$1,144.00

3.45 (0.30%)

GOOGL

Alphabet Class A

$1,148.10

3.22 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

  • 03

    Jun

  • 06

    Jun

  • 19

    Jun

  • 19

    Jun

  • 25

    Jun

  • 27

    Oct

13:07
05/24/19
05/24
13:07
05/24/19
13:07
General news
Baker-Hughes Rig Count N. Amer. data reported »

Week of 5/24 Baker-Hughes…

UAL

United Continental

$81.10

0.19 (0.23%)

, BA

Boeing

$356.58

6.01 (1.71%)

13:07
05/24/19
05/24
13:07
05/24/19
13:07
Periodicals
United extending Boeing 737 Max cancellations through August 3, CNBC reports »

United Airlines (UAL)…

UAL

United Continental

$81.10

0.19 (0.23%)

BA

Boeing

$356.58

6.01 (1.71%)

AAL

American Airlines

$29.41

-0.08 (-0.27%)

LUV

Southwest

$51.33

0.36 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

  • 12

    Jun

  • 12

    Jun

  • 25

    Jul

  • 13

    Nov

BBY

Best Buy

$64.89

-0.9 (-1.37%)

, SSNLF

Samsung

$0.00

(0.00%)

13:04
05/24/19
05/24
13:04
05/24/19
13:04
Periodicals
Best Buy cancels preorders for Samsung's foldable phone, CNN reports »

Best Buy (BBY) is…

BBY

Best Buy

$64.89

-0.9 (-1.37%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

  • 11

    Jun

BHGE

Baker Hughes

$22.28

-0.78 (-3.38%)

13:03
05/24/19
05/24
13:03
05/24/19
13:03
Hot Stocks
Baker Hughes reports U.S. rig count down 4 to 983 rigs »

Baker Hughes reports that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$162.59

1.07 (0.66%)

13:02
05/24/19
05/24
13:02
05/24/19
13:02
Hot Stocks
Visa CFO Vasant Prabhu appointed company vice chairman »

Visa announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 05

    Jun

EHC

Encompass Health

$59.22

-0.315 (-0.53%)

13:01
05/24/19
05/24
13:01
05/24/19
13:01
Hot Stocks
Encompass Health names Kim Sullivan chief human resources officer »

Encompass Health…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

IONS

Ionis Pharmaceuticals

$67.35

0.215 (0.32%)

, BIIB

Biogen

$229.80

0.75 (0.33%)

13:01
05/24/19
05/24
13:01
05/24/19
13:01
Hot Stocks
Ionis, Biogen slip after FDA approves Novartis' Zolgensma for SMA treatment »

Shares of Ionis…

IONS

Ionis Pharmaceuticals

$67.35

0.215 (0.32%)

BIIB

Biogen

$229.80

0.75 (0.33%)

NVS

Novartis

$87.21

2.75 (3.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 31

    May

  • 05

    Jun

  • 06

    Jun

  • 17

    Jun

  • 18

    Jun

XRT

S&P Retail Index SPDR

$41.58

-0.09 (-0.22%)

13:00
05/24/19
05/24
13:00
05/24/19
13:00
Options
Size four-way put spread in SPDR Retail Trust as shares extend losses »

Size four-way put spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RGNX

Regenxbio

$43.60

1.11 (2.61%)

, NVS

Novartis

$87.13

2.67 (3.16%)

12:53
05/24/19
05/24
12:53
05/24/19
12:53
Hot Stocks
Regenxbio up 6% after Novartis receives FDA approval for Zolgensma »

Regenxbio (RGNX) will…

RGNX

Regenxbio

$43.60

1.11 (2.61%)

NVS

Novartis

$87.13

2.67 (3.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

  • 31

    May

NVS

Novartis

$87.04

2.58 (3.05%)

12:47
05/24/19
05/24
12:47
05/24/19
12:47
Hot Stocks
Novartis says wholesale acquisition cost of Zolgensma $2.125M »

AveXis, a Novartis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

TIVO

TiVo

$6.87

0.04 (0.59%)

12:45
05/24/19
05/24
12:45
05/24/19
12:45
Options
TiVo call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jun

12:45
05/24/19
05/24
12:45
05/24/19
12:45
General news
Breaking General news story  »

Week of 5/24 Baker-Hughes…

VWAGY

Volkswagen

$0.00

(0.00%)

12:42
05/24/19
05/24
12:42
05/24/19
12:42
Periodicals
Appeals court rules in favor of Volkswagen diesel car owners, Reuters reports »

A German appeals court…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$56.30

0.85 (1.53%)

, WCG

WellCare

$267.57

-6.89 (-2.51%)

12:42
05/24/19
05/24
12:42
05/24/19
12:42
Periodicals
Third Point confirms Centene stake to CNBC, says WellCare deal in best interest »

CNBC tweeted: "Third…

CNC

Centene

$56.30

0.85 (1.53%)

WCG

WellCare

$267.57

-6.89 (-2.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 23

    Jul

SPY

SPDR S&P 500 ETF Trust

$282.86

0.67 (0.24%)

, IVV

iShares Core S&P 500

$284.83

0.69 (0.24%)

12:40
05/24/19
05/24
12:40
05/24/19
12:40
Technical Analysis
On The Fly: ETF fund flow highlights »

Flows for the past week…

SPY

SPDR S&P 500 ETF Trust

$282.86

0.67 (0.24%)

IVV

iShares Core S&P 500

$284.83

0.69 (0.24%)

XLK

Technology Select Sector SPDR

$73.62

0.33 (0.45%)

SMH

Market Vectors Semiconductor

$100.37

0.23 (0.23%)

SOXX

iShares PHLX Semiconductor ETF

$180.13

0.06 (0.03%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$119.60

0.14 (0.12%)

EEM

iShares MSCI Emerging Markets ETF

$40.00

0.08 (0.20%)

XLU

Utilities SPDR

$59.99

0.07 (0.12%)

XLV

Health Care Select Sector SPDR

$89.56

0.17 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.